ASHI Insights
Jul. 15, 2014

Join us in Denver, for the 40th Annual Meeting!
ASHI
The 40th Annual Meeting site is now live! Visit the annual meeting website for the latest information on this year's meeting including the full program, event information, Denver hot spots and more! www.2014.ASHI-HLA.ORGMore

Registration is open! Become a member when you register
ASHI
New this year! Join ASHI while registering for the meeting and save up to $135 on registration fees. Members who join now are paid through December 2015! Click here to register now. More

International Summer School — Oct. 15 -18, in Boulder, Colorado
ASHI
APPLICATION DEADLINE EXTENDED THROUGH JULY

We're in the final weeks of accepting International Summer School applications. Don't wait another day to send in your application. Not only will you have access to expert programming but you'll also be a short ride away from ASHI's 40th Annual Meeting taking place in Denver, Oct. 20-24.

To allow for intense, interactive discussions, a total of only 50 students will be accepted from all 3 sponsoring societies.

The low tuition fee of $250 includes the following:

For program details and information on how to apply, visit www.ashi-hla.org/events/int-ummer-school.

This year's International Summer School for Histocompatibility and Immunogenetics is organized by ASHI with support from EFI (European Federation for Immunogenetics) and APHIA (Asia-Pacific Histocompatibility and Immunogenetics Association) More

FACT-JACIE International Standards — comments sought
ASHI
FACT has published the draft sixth edition of the FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing and Administration for Hematopoietic Cellular Therapies for inspection and public comment for a 90-day period. Comments will be accepted from April 30, through July 24.

These standards apply to hematopoietic progenitor cells, defined as self-renewing and/or multi-potent stem cells capable of maturation into any of the hematopoietic lineages, lineage-restricted pluri-potent progenitor cells and committed progenitor cells from hematopoietic sources (bone marrow, umbilical cord blood, peripheral blood or other tissue source). These standards also include mononuclear cells, defined as nucleated cells from any hematopoietic tissue source (marrow, peripheral blood, umbilical cord and placental blood) collected for therapeutic use other than as hematopoietic progenitor cells. The standards apply to all phases of collection, processing, storage and administration of these cells, including various minimal manipulations such as removal or enrichment of various cell populations and cryopreservation.

FACT will also publish the draft first edition Common Standards for Cellular Therapies for public review and comment soon. The common standards are derived from current editions of FACT-JACIE Cellular Therapy and NetCord-FACT Cord Blood Standards, and are intended to represent the basic fundamentals of cellular therapy that can be applied to any cell source or therapeutic application and more than minimal manipulation. Instructions for submitting comments on those Standards will be announced when the draft is published.

Description and Instructions for FACT-JACIE Standards

Draft FACT-JACIE Standards

The Hematopoietic Stem Cell Transplant arm of the ASHI National Clinical Affairs Committee have prepared an official ASHI response to the 6th edition of the FACT-JACIE Standards. Click here to read ASHI's official comments in their entirety.

To submit your own comments for the draft FACT-JACIE Standards, follow the steps below. Comments will be accepted until July 24.

1. Access the comment form at http://www.surveymonkey.com/s/HCTcomments

2. Type in your contact information and comments on the form. Fill in all fields so that the Standards Committee fully understands your position.

3. Submit the form when finished. Once the form is submitted, it cannot be changed. However, additional comments may be submitted by completing the form again. There is no limit to the number of forms that can be submitted.More

Pediatric celiac disease more common with HLA haplotype
Medscape (free subscription)
Human leukocyte antigen (HLA) haplotype DR3-DQ2 is associated with dosage-dependent increases in risk for celiac disease autoimmunity and celiac disease in young children, according to a study published in the July 3 issue of the New England Journal of Medicine. Although most patients with celiac disease have at least 1 copy of DR3-DQ2 or DR4-DQ8, these haplotypes are also common in the general population. DR3-DQ2 carries a higher risk than DR4-DQ8. More

Graft-host tolerance in bone marrow transplant chimeras. Absence of graft-versus-host disease is associated with unresponsiveness to minor histocompatibility antigens expressed by all tissues
American Society of Hematology
Because bone marrow (BM) transplantation is used with increasing frequency, it is important to elucidate the mechanisms involved in the establishment of tolerance to host minor histocompatibility antigens (MIHA) in recipients transplanted with T-cell-undepleted marrow grafts. It has been previously shown that BM chimeras transplanted across MiHA barriers showed specific unresponsiveness to MiHA expressed on recipient-type concanavalin A blasts. Because expression of many MiHA is tissue-specific, scientists wanted to determine if chimera T-lymphocytes would be tolerant to MiHA expressed by all host tissues and organs.More

Non-myeloablative allogeneic HSCT shows promise for adults with sickle cell disease
Healio
Adults with sickle cell phenotype achieved a high rate of stable mixed-donor chimerism and disease reversal after they underwent non-myeloablative human leukocyte antigen-matched sibling allogeneic hematopoietic stem cell transplantation, according to study results. Researchers observed the benefits in patients with or without thalassemia. The analysis included 30 patients with severe sickle cell disease.More